| scholarly article | Q13442814 |
| P50 | author | Michael J. Econs | Q40973951 |
| Bettina Lorenz-Depiereux | Q47172989 | ||
| Hans Zischka | Q49645559 | ||
| P2093 | author name string | Tim M Strom | |
| Kenneth E White | |||
| Anna Benet-Pagès | |||
| Bettina Lorenz-Depiereux | |||
| P433 | issue | 2 | |
| P304 | page(s) | 455-462 | |
| P577 | publication date | 2004-08-01 | |
| P1433 | published in | Bone | Q15755003 |
| P1476 | title | FGF23 is processed by proprotein convertases but not by PHEX. | |
| P478 | volume | 35 |
| Q36308619 | "Phosphatonins" and the regulation of phosphorus homeostasis |
| Q37552700 | A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease |
| Q37216979 | A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features |
| Q36213739 | A clinical and molecular genetic study of hypophosphatemic rickets in children |
| Q28593754 | Amelogenesis imperfecta and other biomineralization defects in Fam20a and Fam20c null mice |
| Q39033165 | An autosomal dominant hypophosphatemic rickets phenotype in a Tunisian family caused by a new FGF23 missense mutation |
| Q33650430 | Analysis of Thisbe and Pyramus functional domains reveals evidence for cleavage of Drosophila FGFs |
| Q38344729 | Anti-idiotypic antibody mimicking a T-antigen-specific lectin inhibits human epithelial tumor cell proliferation |
| Q35105384 | Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. |
| Q33736093 | Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active |
| Q37641052 | Clinical relevance of FGF-23 in chronic kidney disease |
| Q34251323 | Cooperative Role of NF-κB and Poly(ADP-ribose) Polymerase 1 (PARP-1) in the TNF-induced Inhibition of PHEX Expression in Osteoblasts |
| Q38230408 | Diagnostic Modalities for FGF23-Producing Tumors in Patients with Tumor-Induced Osteomalacia |
| Q37092161 | Dosage effect of a Phex mutation in a murine model of X-linked hypophosphatemia |
| Q36554782 | Emerging role of a phosphatonin in mineral homeostasis and its derangements. |
| Q36982323 | Endocrine functions of bone in mineral metabolism regulation. |
| Q37991256 | Evidence for FGF23 involvement in a bone-kidney axis regulating bone mineralization and systemic phosphate and vitamin D homeostasis. |
| Q91142496 | Evolving concepts in the pathogenesis of uraemic cardiomyopathy |
| Q30393982 | Extending the family table: Insights from beyond vertebrates into the regulation of embryonic development by FGFs |
| Q54960612 | FGF23 Actions on Target Tissues-With and Without Klotho. |
| Q90624325 | FGF23 and Associated Disorders of Phosphate Wasting |
| Q64040255 | FGF23 and its role in X-linked hypophosphatemia-related morbidity |
| Q35707031 | FGF23 in skeletal modeling and remodeling |
| Q36571281 | FGF23 is endogenously phosphorylated in bone cells |
| Q33793927 | FGF23 is synthesised locally by renal tubules and activates injury-primed fibroblasts |
| Q46808011 | FGF23, a "new" hormone regulating phosphate homeostasis and vitamin D metabolism |
| Q35203191 | Familial tumoral calcinosis: from characterization of a rare phenotype to the pathogenesis of ectopic calcification |
| Q26829294 | Fibroblast growth factor 23 |
| Q88633335 | Fibroblast growth factor 23 and Klotho contribute to airway inflammation |
| Q36216951 | Fibroblast growth factor 23 and its receptors |
| Q38072361 | Fibroblast growth factor 23: associations with cardiovascular disease and mortality in chronic kidney disease |
| Q90184135 | Functional analysis of a de novo mutation c.1692 del A of the PHEX gene in a Chinese family with X-linked hypophosphataemic rickets |
| Q34014158 | Genetic diagnosis of X-linked dominant Hypophosphatemic Rickets in a cohort study: tubular reabsorption of phosphate and 1,25(OH)2D serum levels are associated with PHEX mutation type. |
| Q38244118 | Genetic diseases of renal phosphate handling |
| Q98944964 | Genome-wide association study for circulating fibroblast growth factor 21 and 23 |
| Q55689205 | HYPOPHOSPHATEMIC RICKETS: CASE REPORT. |
| Q37798160 | Hereditary disorders of renal phosphate wasting |
| Q24540520 | Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3. |
| Q39118846 | Heritable and acquired disorders of phosphate metabolism: Etiologies involving FGF23 and current therapeutics |
| Q36468902 | Hexa-D-arginine treatment increases 7B2•PC2 activity in hyp-mouse osteoblasts and rescues the HYP phenotype. |
| Q35533372 | Hyperphosphatemic familial tumoral calcinosis: odontostomatologic management and pathological features. |
| Q56627579 | Hypophosphatemic rickets |
| Q36658985 | Hypophosphatemic rickets and osteomalacia |
| Q46776591 | Hypophosphatemic rickets: results of a long-term follow-up |
| Q34069793 | Hypophosphatemic rickets: revealing novel control points for phosphate homeostasis |
| Q48295533 | Impact of Conventional Medical Therapy on Bone Mineral Density and Bone Turnover in Adult Patients with X-Linked Hypophosphatemia: A 6-Year Prospective Cohort Study. |
| Q33634310 | Increased bone volume and correction of HYP mouse hypophosphatemia in the Klotho/HYP mouse |
| Q37118591 | Inherited hypophosphatemic disorders in children and the evolving mechanisms of phosphate regulation |
| Q36911899 | Insights from genetic disorders of phosphate homeostasis |
| Q36609737 | Intact fibroblast growth factor 23 and fragments in plasma from Gambian children |
| Q35497877 | Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans |
| Q37851395 | Is fibroblast growth factor 23 a harbinger of mortality in CKD? |
| Q37488973 | Kidney and phosphate metabolism |
| Q39411802 | Mechanism of FGF23 processing in fibrous dysplasia. |
| Q38208813 | Molecular bases of diseases characterized by hypophosphatemia and phosphaturia: new understanding |
| Q35441666 | Molecular basis of Klotho: from gene to function in aging |
| Q38081019 | Osteocyte regulation of phosphate homeostasis and bone mineralization underlies the pathophysiology of the heritable disorders of rickets and osteomalacia |
| Q41137474 | PAI-1 is a critical regulator of FGF23 homeostasis |
| Q36846110 | Pathogenic role of Fgf23 in Dmp1-null mice. |
| Q35920063 | Phosphate: known and potential roles during development and regeneration of teeth and supporting structures |
| Q42230267 | Phosphatonins: physiological role and pathological changes |
| Q35975746 | Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity |
| Q24321247 | Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation |
| Q36216962 | Post-translational modification of Fibroblast Growth Factor 23. |
| Q38514648 | Posttranslational processing of FGF23 in osteocytes during the osteoblast to osteocyte transition |
| Q28275381 | Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X-linked hypophosphatemia |
| Q34631794 | Recent advances in renal phosphate handling |
| Q28301682 | Recent advances in the renal-skeletal-gut axis that controls phosphate homeostasis |
| Q36739668 | Regulation of phosphate homeostasis by the phosphatonins and other novel mediators |
| Q35151453 | Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism |
| Q28511009 | Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia |
| Q26852624 | Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism |
| Q37153990 | Studies of the DMP1 57-kDa functional domain both in vivo and in vitro |
| Q35992810 | Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP) |
| Q39049485 | Sympathetic activation induces skeletal Fgf23 expression in a circadian rhythm-dependent manner |
| Q64118923 | The EPO-FGF23 Signaling Pathway in Erythroid Progenitor Cells: Opening a New Area of Research |
| Q92959917 | The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia |
| Q36860289 | The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis |
| Q33781943 | The ever-expanding conundrum of primary osteoporosis: aetiopathogenesis, diagnosis, and treatment. |
| Q37771349 | The phosphate regulating hormone fibroblast growth factor-23. |
| Q38020094 | The role of FGF23 in CKD--with or without Klotho. |
| Q36963471 | The role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy |
| Q53989980 | The role of fibroblast growth factor-23 in cardiorenal syndrome. |
| Q37334547 | The skeleton: endocrine regulator of phosphate homeostasis |
| Q33835743 | The use of fibroblast growth factor 23 testing in patients with kidney disease |
| Q46711944 | Treatment of ear and bone disease in the Phex mouse mutant with dietary supplementation. |
| Q38878795 | Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats. |
| Q81857590 | [Genetic hypophosphatemia: recent advances in physiopathogenic concept] |
Search more.